A new study from the COV-BOOST trial looking at fourth doses of COVID-19 vaccine has been published in the Lancet Infectious Diseases.
The study examines safety and immune response (antibodies and T-cells) after a fourth dose of mRNA COVID-19 vaccine, and compares immune response after a fourth dose with that after a third dose. In the study, 166 people who had received a third dose of Pfizer (following Pfizer or AstraZeneca initial doses in June 2021) were randomised to receive either full dose Pfizer or half dose Moderna as a fourth dose.
Journalists dialled in to this briefing to hear from authors of the study describe and explain their results.
Prof Saul Faust, COV-BOOST Chief Investigator and NISEC co-investigator, and Director of NIHR Southampton Clinical Research Facility and Professor of Paediatric Immunology and Infectious Diseases at the University of Southampton